Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04024059 · ClinicalTrials.gov registry record · NA
Contingency Management to Enhance Office-Based Buprenorphine Treatment
A NA study, sponsored by Johns Hopkins University.
- Completed
- Registry status
- NA
- Development phase
- 375
- Enrollment target
NCT04024059: Completed NA study, sponsored by Johns Hopkins University.
NCT04024059 is a NA study that has completed, run by Johns Hopkins University. The registered enrollment target is 375 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04024059, a NA study, has completed, sponsored by Johns Hopkins University.
- COMPLETED
- Registry status
- NA
- Development phase
- 375 participants
- Enrollment target
Study Summary
Contingency Management interventions provide incentives to substance abuse patients when patients meet therapeutic goals. This project will compare the effectiveness of two Contingency Management interventions (which the investigators have named "Buprenorphine Adherence and Opiate Abstinence" and "Buprenorphine Adherence Only") and Standard Medical Management for treating adults with opioid use disorder. Participants (N=375) will be randomly assigned to one of the three groups. Buprenorphine Adherence and Opiate Abstinence and Buprenorphine Adherence Only participants will receive incentives for daily buprenorphine use. Buprenorphine Adherence and Opiate Abstinence participants also will receive incentives for providing opiate-negative saliva samples. Daily buprenorphine use and opiate abstinence will both be remotely verified using smartphone-enabled video directly observed therapy (Video DOT). All participants will be receiving or referred to receive buprenorphine treatment and will complete assessments every 4 weeks during a 12-week intervention period.
Interventions
- BEHAVIORAL Contingency Management for adherence
- BEHAVIORAL Contingency Management for abstinence
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 375 participants |
| Start Date | 2020-01-31 |
| Est. Completion | 2024-07-01 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04024059
The ClinicalTrials.gov registry entry for NCT04024059 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 375 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Johns Hopkins University, which has 1,448 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Contingency Management for adherence is the first listed.
NCT04024059 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04024059 about?
NCT04024059 is a clinical study titled "Contingency Management to Enhance Office-Based Buprenorphine Treatment". Contingency Management interventions provide incentives to substance abuse patients when patients meet therapeutic goals. This project will compare the effectiveness of two Contingency Management interventions (which the investigators have named "Buprenorphine Adherence and Opiate Abstinence" and "B...
What is the current status of trial NCT04024059?
This trial is currently completed. It is a NA study. The enrollment target is 375 participants. The study started on 2020-01-31. Estimated completion is 2024-07-01.
What interventions are being tested in trial NCT04024059?
The interventions under investigation include: Contingency Management for adherence (BEHAVIORAL), Contingency Management for abstinence (BEHAVIORAL).
Who is sponsoring clinical trial NCT04024059?
This trial is sponsored by Johns Hopkins University, which has 1,448 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.